Morgan Stanley analyst Craig Hettenbach maintained a Buy rating on Hinge Health, Inc. Class A today and set a price target of $72.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Craig Hettenbach has given his Buy rating due to a combination of factors tied to Hinge Health’s operating momentum and market position. He highlights that first‑quarter app downloads jumped about 60% year over year, signaling strong net new member growth, and that Hinge’s app engagement is running roughly three times that of its nearest MSK competitor, underscoring clear category leadership.
He also notes that the company is tracking ahead of its long‑term target for covered lives, with the largest onboarding period occurring in Q1, and sees room for upside versus the 2026 outlook of 25% revenue growth and $151–$156 million in adjusted EBIT as member yield improves. Despite recent share price weakness driven by broad worries over AI disruption in software, he views upcoming Q1 earnings as a favorable catalyst, emphasizing that Hinge is actively using AI to scale its platform rather than being structurally threatened by it.
In another report released on April 8, Evercore ISI also maintained a Buy rating on the stock with a $45.00 price target.